Evidence map›Paper›PMID 42786283›Full record

ArticleCell death and differentiation2026

Hepatitis B virus protein X promotes survival and loss of hepatocyte identity in a differentiated human liver organoid system.

Xingyu Fan, Bram Torenvliet, Alexandros Galaras, Tanvir Hossain, Lincon Hasda, Martin E van Royen, Helmuth Gehart, Lili Zhao, Eleni Katsoni, Tsung Wai Kan and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xingyu Fan *Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Bram Torenvliet *Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Alexandros GalarasInstitute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
Tanvir HossainDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-4765-6600
Lincon HasdaDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Martin E van RoyenDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Helmuth GehartETH Zurich, Institute of Molecular Health Sciences, Zürich, Schweiz.ORCID http://orcid.org/0000-0002-9165-5824
Lili ZhaoDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Eleni KatsoniInstitute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.ORCID http://orcid.org/0009-0009-8265-7092
Tsung Wai KanDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Panagiotis MoulosInstitute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
Shringar RaoDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Farzin PourfarzadHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.
Javier Frias AldeguerHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.ORCID http://orcid.org/0000-0003-2465-2081
Sylvia F BojHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.
Pantelis HatzisInstitute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.ORCID http://orcid.org/0000-0001-5002-7728
Robert-Jan PalstraDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Tokameh MahmoudiDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. t.mahmoudi@erasmusmc.nl.ORCID http://orcid.org/0000-0002-2060-9353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) drives hepatocellular carcinoma in part through the activity of its X protein (HBx), yet the mechanisms by which HBx alters hepatocyte function remain incompletely understood. Progress has been limited by the lack of relevant human models that support controlled HBx expression in mature hepatocytes. To address this limitation, here, we use an improved hepatocyte-like organoid (HLO) platform that supports enhanced hepatocyte maturation to investigate HBx function in a differentiated hepatocyte context. Adult stem cell-derived HLOs were differentiated using an optimized protocol to generate hepatocyte-like cells with enhanced maturation and transcriptional similarity to primary liver tissue. HBx function was interrogated using both cognate promoter-driven expression and doxycycline-inducible systems across multiple donor-derived organoid lines. Transcriptomic, pathway, and single-cell imaging analyses were performed to assess the impact of HBx expression on hepatocytes. HBx expression consistently suppressed apoptosis-associated transcripts and reduced expression of core hepatocyte identity genes, including CYP3A4. Pathway analysis revealed downregulation of liver-specific functions, including metabolism, detoxification, complement, and coagulation. At the single-cell level, higher HBx expression was associated with reduced caspase 3/7 activation following apoptotic challenge and decreased hepatocyte marker expression. Functionally, the expression of HBx increased resistance to apoptosis and enhanced the ability of differentiated hepatocyte-like cells to revert to a proliferative state. HBx expression in differentiated human liver organoids reduces apoptosis and impairs hepatocyte identity, consistently across donors and expression systems. Together, these findings support a model in which HBx promotes a survival-permissive state of reduced hepatocyte differentiation. This state may contribute to early HBV-driven tumorigenesis. This HLO platform provides a relevant system to dissect HBV-host interactions and reveals a mechanism by which HBV may prime the liver for malignant transformation. IMPACT AND IMPLICATIONS: Understanding how HBV promotes hepatocellular carcinoma remains a critical challenge, partly due to the lack of physiologically relevant human derived model systems to study HBx function. Using a differentiated adult human liver organoid system, we show that HBx simultaneously suppresses apoptosis and reduces hepatocyte differentiation, providing a mechanistic framework for how HBV may prime hepatocytes for malignant transformation. These findings are particularly relevant for researchers studying HBV pathogenesis and liver cancer, as well as for clinicians aiming to better understand early disease progression. While further validation in more complex multicellular systems is needed, this platform can support the identification of HBx-targeted therapeutic strategies and guide the development of improved adult human derived models for virus-host interaction studies.

Identifiers

PMID42786283

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.